首页> 外文OA文献 >Abatacept for GVHD Prophylaxis after Hematopoietic Stem Cell Transplantation (HCT) for Pediatric Sickle Cell Disease (SCD): A Sickle Transplant Alliance for Research (STAR) Trial

【2h】

Abatacept for GVHD Prophylaxis after Hematopoietic Stem Cell Transplantation (HCT) for Pediatric Sickle Cell Disease (SCD): A Sickle Transplant Alliance for Research (STAR) Trial

机译：用于造血干细胞移植后GVHD预防的GVHD预防（HCT）用于小儿镰状细胞疾病（SCD）：镰刀移植联盟研究（星级）试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Sonali Chaudhury; Joe Laskowski; Hemalatha G. Rangarajan; Allistair Abraham; Ann E. Haight; Gregory M.T. Guilcher; Jean Sosna; Chalitha Robinson; John Horan; Monica Bhatia;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Abatacept for GVHD Prophylaxis after Hematopoietic Stem Cell Transplantation (HCT) for Pediatric Sickle Cell Disease (SCD): A Sickle Transplant Alliance for Research (STAR) Trial [J] . Sonali Chaudhury, Joe Laskowski, Hemalatha G. Rangarajan, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2018,第3期

机译：用于造血干细胞移植后GVHD预防的GVHD预防（HCT）用于小儿镰状细胞疾病（SCD）：镰刀移植联盟研究（星级）试验
2. Abatacept for GVHD Prophylaxis after Hematopoietic Stem Cell Transplantation (HCT) for Pediatric Sickle Cell Disease (SCD): A Sickle Transplant Alliance for Research (STAR) Trial [J] . Sonali Chaudhury, Joe Laskowski, Hemalatha G. Rangarajan, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2018,第3期

机译：用于造血干细胞移植后GVHD预防的GVHD预防（HCT）用于小儿镰状细胞疾病（SCD）：镰刀移植联盟研究（星级）试验
3. PHARMACOKINETICS AND CLINICAL OUTCOMES OF INTRAVENOUS BUSULFAN ADMINISTERED TWICE DAILY DURING CONDITIONING IN PEDIATRIC RECIPIENTS PRIOR TO FAMILIAL HAPLOIDENTICAL(FHI) T-CELL DEPLETED (TCD) ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AlloHSCT) IN HIGH RISK SICKLE CELL DISEASE (SCD) [J] . Mehta Brinda, Klejmont Liana, Milone Michael, Pediatric blood & cancer . 2016,第Suppla1期

机译：患儿全亲肝病（TCD）异基因造血干细胞病（TCD）完全性干细胞病性干细胞病原发性干细胞病（PC）病史前，每日两次在儿科患者接受条件治疗期间，静脉bususfan不良反应的药代动力学和临床结果
4. THE EFFECT OF INHIBITORY KILLER-CELL IG-LIKE RECEPTOR (IKIR) MATCHING IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) [C] . David Senitzer, Joel Y. Sun, Arisa Oki, Clinical Histocompatibility Workshop. . 2009

机译：同种异体造血细胞移植（HCT）中抑制杀伤细胞IG样受体（IKIR）匹配的影响
5. Donor selection for patients undergoing allogeneic hematopoietic stem cell transplantation: Assessment of the priorities of Canadian hematopoietic stem cell transplant physicians. [D] . Tay, Jason. 2009

机译：接受同种异体造血干细胞移植的患者的供体选择：加拿大造血干细胞移植医生的优先事项评估。
6. Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease [O] . Alexander Ngwube, Niketa Shah, Kamar Godder, 2020

机译：AbataCept在患有严重镰状细胞疾病的儿童的无关供体干细胞移植中的GVHD预防有效
7. Outcomes of Gene Therapy for Severe Sickle Cell Disease (SCD) via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral ßAT87Q-Globin Vector [O] . Sandeep Soni, John F. Tisdale, Matthew Hsieh, 2016

机译：通过自体造血干细胞移植转导的基因治疗对严重镰状细胞疾病（SCD）的结果转导βAT87Q-珠蛋白载体

Abatacept for GVHD Prophylaxis after Hematopoietic Stem Cell Transplantation (HCT) for Pediatric Sickle Cell Disease (SCD): A Sickle Transplant Alliance for Research (STAR) Trial

著录项

相似文献

相关主题

期刊订阅